Physician profile
Amy Phillips
NPI 1447729611
$4,087.75
in general payments reported to CMS, 2019-2025
28 companies · $888 in 2025
The $888 reported for 2025 was more than what 86% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $722 · 2023: $1,237 · 2024: $1,240 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,341 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,340.76 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $671.49 | 2022-2025 | Farxiga, Lokelma, Evusheld |
| Aurinia Pharma U.S., INC. | $419.71 | 2022-2025 | Lupkynis |
| Amgen INC. | $358.26 | 2022-2025 | Tavneos, Krystexxa |
| Calliditas Therapeutics US INC. | $357.31 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $267.08 | 2023-2025 | |
| Travere Therapeutics, INC. | $238.86 | 2022-2025 | |
| Glaxosmithkline, LLC. | $233.60 | 2022-2025 | Benlysta, Jesduvroq, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $189.21 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $181.49 | 2022-2025 | Jynarque |
| Veloxis Pharmaceuticals, INC. | $157.46 | 2022-2025 | Envarsus |
| Vifor Pharma, INC. | $132.75 | 2022-2024 | Veltassa |
| Akebia Therapeutics INC | $131.19 | 2024-2025 | Vafseo, Auryxia |
| Alexion Pharmaceuticals, INC. | $90.55 | 2023-2024 | Ultomiris |
| Horizon Therapeutics Plc | $84.23 | 2022-2023 | Krystexxa |
| Lilly USA, LLC | $74.19 | 2024-2025 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $69.97 | 2022-2024 | Terlivaz |
| Novo Nordisk INC | $68.59 | 2024-2025 | Rivfloza, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.25 | 2023-2025 | Jardiance |
| Cormedix INC. | $60.92 | 2024 | Defencath |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.33 | 2023-2024 | Xifaxan |
| Opko Pharmaceuticals, LLC | $35.55 | 2023 | Rayaldee |
| Ultragenyx Pharmaceutical INC. | $35.39 | 2022-2024 | Crysvita |
| Kyowa Kirin, INC. | $25.40 | 2025 | |
| Alnylam Pharmaceuticals INC. | $24.41 | 2022 | |
| Ani Pharmaceuticals, INC. | $19.59 | 2023 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.08 | 2025 | Voyxact |
| Recordati_rare_diseases_inc. | $19.07 | 2023 | Cystadrops |
| Takeda Pharmaceuticals U.S.A., INC. | $17.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.